Business Development
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson’s Disease
ROCKVILLE, Md. and SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX: 009420.KS) and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620.KS) announced that they have entered into a co-development agreement with NurrOn Pharmaceuticals Inc., a Boston-based preclinical-stage biopharma.
Clover Expands Sales and Distribution Network for Upcoming Quadrivalent Seasonal Influenza Vaccine Launch in China
SHANGHAI, China, May 24, 2023 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, announced that it has established a commercial partnership with Keyuan Xinhai (Beijing) Medical Products Trading Co. Ltd. (Kyuan Trade), a leading pharmaceutical import and distribution company in China, as it prepares for the commercial launch of AdimFlu-S (QIS), the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. Clover expects to launch AdimFlu-S (QIS) in H2 2023.
Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis
SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences ("Keymed", HKEX: 02162), today announced a collaboration to jointly discover and develop first-in-class siRNA therapeutics for Glomerulonephritis (also referred as severe kidney diseases).
Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer
SHANGHAI, May 18, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu Corporation ("UroViu").
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
SHANGHAI, May 12, 2023 /PRNewswire/ -- LaNova Medicines Ltd. ("LaNova Medicines") announced today it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D).
Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
HONG KONG & SUZHOU, China & SHANGHAI--(BUSINESS WIRE)-- Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2).
Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China
HANGZHOU, China, May 8, 2023 /PRNewswire/ -- Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply agreements to provide INBRIJA® in Greater China (Mainland China, Taiwan, Hong Kong, and Macao). INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
Bliss Biopharmaceutical Enters Into a Clinical Trial Collaboration Agreement With an Option of Strategic Collaboration With Eisai for BB-1701
HANGZHOU, China, May 7, 2023 /PRNewswire/ -- Bliss Biopharmaceutical (Hangzhou) Co., Ltd, ("BlissBio") a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced a clinical trial collaboration agreement with option for strategic collaboration with Eisai Co., Ltd. ("Eisai"), for BB-1701, eribulin-payload based ADC directed against Human Epidermal Growth Factor Receptor 2 (HER2) for the treatment of cancers.
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
PEARL RIVER, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreements to provide INBRIJA® in China.
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck
CAMBRIDGE, Mass. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines for the treatment of central nervous system (CNS) diseases, announced today the signing of an exclusive, worldwide license and option agreement with Lundbeck, a leading pharmaceutical company focusing on the development of innovative medicines treating neurological and psychiatric diseases.
